NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SHILPAMED · data 2026-10-31
Shilpa Medicare Limited
In plain words
Price: 12.7% below its 52-week high of ₹1,095.
Delivery: 41.9% of traded shares were kept for delivery over the last 10 sessions, against 40.4% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,682 cr |
| Net profit (last 12 months) | ₹297 cr |
| Sales growth, 3 years (yearly) | 13.8% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 40.1% (-4.1 pts in a year), pledged 4.9%, institutions 20.4%.
P/E 62.9, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE 9.8%, ROCE 9.0%, operating margin 21.0%: how much profit it earns on the money it uses.
Debt/equity 0.25, Profit growth — and sales growth 13.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Healthy operating margin (21.0%).
- Promoters have pledged 4.9% of their shares.
- Promoters cut their holding by 4.1 points in a year.
- Expensive on earnings (P/E 62.9).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
19/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 14/30: Delivery 44.5% over the last 20 sessions vs 25.7% in the 40 before (1.73x); shares delivered per day 0.67x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Bonus
- 4 Sept 26Dividend Dividend ₹0.6 (ex-date) -1.7% next session
- 3 Oct 25Bonus Bonus 1:1 (ex-date)
- 17 Sept 25Dividend Dividend ₹1 (ex-date) -1.1% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 40.13% | 40.13% | 40.13% | 40.13% |
| Foreign institutions (FII) | 12.11% | 11.38% | 11.08% | 10.97% |
| Domestic institutions (DII) | 8.26% | 8.05% | 8.58% | 8.33% |
| Mutual funds | 4.20% | 4.21% | 5.15% | 5.20% |
| Retail investors | 16.86% | 16.44% | 15.32% | 15.03% |
| Number of shareholders | 87,477 | 60,926 | 53,410 | 53,799 |
Common questions
How much do promoters hold in Shilpa Medicare Limited?
Promoters held 40.13% of Shilpa Medicare Limited at the end of Sept 2026, with 4.90% of promoter shares pledged.
Is Shilpa Medicare Limited debt-free?
Its latest reported debt-to-equity ratio is 0.25.
What is Shilpa Medicare Limited's P/E ratio?
About 62.9, based on the last 12 months' earnings and a price of ₹955.6 (data 2026-10-31).
What is the 52-week high and low of Shilpa Medicare Limited?
The 52-week high is ₹1,095 and the 52-week low is ₹259.5.
Mutual funds holding Shilpa Medicare Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 3 schemes holding about ₹107 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| ADITYA BIRLA SUN LIFE SMALL CAP FUND | Aditya Birla Sun Life Mutual Fund | 0.95% | ₹58 cr |
| ADITYA BIRLA SUN LIFE MANUFACTURING EQUITY FUND | Aditya Birla Sun Life Mutual Fund | 2.38% | ₹33 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 1.43% | ₹15 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Shilpa Medicare Limited | ₹955.6 | ₹18,671 cr | 62.9 | — | 9.8% | 9% | 0.25 | +166.2% |
| OneSource Specialty Pharma Limited | ₹1,563 | ₹17,926 cr | — | 3 | -1.3% | -0.1% | 0.26 | -15.1% |
| Caplin Point Laboratories Limited | ₹2,325.6 | ₹17,672 cr | 26.7 | — | 19.9% | 20.9% | 0 | +15.2% |
| Alivus Life Sciences Ltd | ₹1,415.3 | ₹17,284 cr | 26 | 4.8 | 18.4% | 22.4% | 0.02 | +55.2% |
| Cohance Lifesciences Ltd | ₹444.3 | ₹17,005 cr | 161 | 4.4 | 6.4% | 4.6% | 0.1 | -44.0% |
| PFIZER LIMITED | ₹3,687.8 | ₹16,867 cr | 23 | — | 17.2% | 20% | 0.02 | -30.0% |
Compare SHILPAMED with ONESOURCE in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SHILPAMED in NSE Scanner →